Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues.
Cozzi R, Ambrosio MR, Attanasio R, Bozzao A, De Marinis L, De Menis E, Guastamacchia E, Lania A, Lasio G, Logoluso F, Maffei P, Poggi M, Toscano V, Zini M, Chanson P, Katznelson L. Cozzi R, et al. Among authors: de menis e. Endocr Metab Immune Disord Drug Targets. 2020;20(8):1144-1155. doi: 10.2174/1871530320666200129113328. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31995025 Free PMC article. Review.
Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues.
Cozzi R, Ambrosio MR, Attanasio R, Bozzao A, De Marinis L, De Menis E, Guastamacchia E, Lania A, Lasio G, Logoluso F, Maffei P, Poggi M, Toscano V, Zini M, Chanson P, Katznelson L. Cozzi R, et al. Among authors: de menis e. Endocr Metab Immune Disord Drug Targets. 2020;20(8):1133-1143. doi: 10.2174/1871530320666200127103320. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31985386 Free PMC article. Review.
Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.
Cozzi R, Ambrosio MR, Attanasio R, Battista C, Bozzao A, Caputo M, Ciccarelli E, De Marinis L, De Menis E, Faustini Fustini M, Grimaldi F, Lania A, Lasio G, Logoluso F, Losa M, Maffei P, Milani D, Poggi M, Zini M, Katznelson L, Luger A, Poiana C. Cozzi R, et al. Among authors: de menis e. Eur J Endocrinol. 2022 Feb 3;186(3):P1-P33. doi: 10.1530/EJE-21-0977. Eur J Endocrinol. 2022. PMID: 35000899 Free PMC article.
Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study.
Attanasio R, Lanzi R, Losa M, Valentini F, Grimaldi F, De Menis E, Davì MV, Battista C, Castello R, Cremonini N, Razzore P, Rosato F, Montini M, Cozzi R. Attanasio R, et al. Among authors: de menis e. Endocr Pract. 2008 Oct;14(7):846-55. doi: 10.4158/EP.14.7.846. Endocr Pract. 2008. PMID: 18996812 Clinical Trial.
Pegvisomant in acromegaly: an update.
Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, De Menis E, Degli Uberti E, Giorgino F, Grottoli S, Lania AG, Maffei P, Pivonello R, Ghigo E. Giustina A, et al. Among authors: de menis e, de marinis l. J Endocrinol Invest. 2017 Jun;40(6):577-589. doi: 10.1007/s40618-017-0614-1. Epub 2017 Feb 7. J Endocrinol Invest. 2017. PMID: 28176221 Free PMC article. Review.
Pegvisomant in acromegaly: why, when, how.
Colao A, Arnaldi G, Beck-Peccoz P, Cannavò S, Cozzi R, degli Uberti E, De Marinis L, De Menis E, Ferone D, Gasco V, Giustina A, Grottoli S, Lombardi G, Maffei P, Martino E, Minuto F, Pivonello R, Ghigo E. Colao A, et al. Among authors: de menis e, de marinis l. J Endocrinol Invest. 2007 Sep;30(8):693-9. doi: 10.1007/BF03347452. J Endocrinol Invest. 2007. PMID: 17923803 Review. No abstract available.
Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.
Reimondo G, Bondanelli M, Ambrosio MR, Grimaldi F, Zaggia B, Zatelli MC, Allasino B, Laino F, Aroasio E, Termine A, Conton P, Paoletta A, Demenis E, Uberti ED, Terzolo M. Reimondo G, et al. Endocrine. 2014 Feb;45(1):122-7. doi: 10.1007/s12020-013-9996-9. Epub 2013 Jun 21. Endocrine. 2014. PMID: 23794116 Free article.
Acromegaly is associated with increased cancer risk: a survey in Italy.
Terzolo M, Reimondo G, Berchialla P, Ferrante E, Malchiodi E, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavo S, Ferone D, Montini M, Bondanelli M, De Menis E, Martini C, Puxeddu E, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Peraga G, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Berton A, Serban AL, Baldelli R, Fatti LM, Colao A, Arosio M; Italian Study Group of Acromegaly. Terzolo M, et al. Among authors: de menis e, de marinis l. Endocr Relat Cancer. 2017 Sep;24(9):495-504. doi: 10.1530/ERC-16-0553. Epub 2017 Jul 14. Endocr Relat Cancer. 2017. PMID: 28710115 Free article.
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline.
Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo' S, De Marinis L, De Menis E, Grottoli S, Pivonello R. Giustina A, et al. Among authors: de menis e, de marinis l. J Endocrinol Invest. 2014 Oct;37(10):1017-30. doi: 10.1007/s40618-014-0146-x. Epub 2014 Sep 23. J Endocrinol Invest. 2014. PMID: 25245336 Free PMC article. No abstract available.
Correction to: Pegvisomant in acromegaly: an update.
Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, De Menis E, Degli Uberti E, Giorgino F, Grottoli S, Lania AG, Maffei P, Pivonello R, Ghigo E. Giustina A, et al. Among authors: de menis e. J Endocrinol Invest. 2018 Feb;41(2):267. doi: 10.1007/s40618-017-0800-1. J Endocrinol Invest. 2018. PMID: 29285678 Free PMC article.
70 results